In recent years, immunotherapy represented by PD-1 inhibitors has revolutionized the treatment of lung cancer, but the accompanying immune-related side reactions cannot be ignored, which includes the outbreak of TB after the use of PD-1 inhibitors. This evidence concerns the gene PDCD1 and lung carcinoma.